Sharon Mates, Chairman, President & CEO at Intra-Cellular Therapies, Inc. (ITCI), sold 33,083 shares at $55.00 ($1.8M) on 2022-12-13, disclosed to the SEC on 2022-12-15.
Open-market sale of $1.8M ITCI by Chairman, President & CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| ITCI | SELL | 2024-08-28 | $14.1M | — | Filing → |
| ITCI | SELL | 2024-08-23 | $18.0M | — | Filing → |
| ITCI | SELL | 2024-03-11 | $8.1M | — | Filing → |